Alvotech (NASDAQ:ALVO) and Dr. Reddy’s Laboratories (NYSE:RDY) have entered into a collaboration and license agreement to ...

MoonLake Immunotherapeutics shares surged 31% after the Financial Times reported, citing unnamed sources, that the company had rejected an initial acquisition offer by Merck & Co. for more than $3 ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

Artisan Partners, an investment management company, released its “Artisan Value Fund” first quarter 2025 investor letter. A ...

Barreling toward the loss of exclusivity on its blockbuster oncology therapy Keytruda, Merck & Co. has reportedly offered $3 ...

Quality of life improvements were […] US drug giant Merck & Co Inc (NYSE:MRK) reportedly approached Swiss biotech MoonLake Immunotherapeutics (NASDAQ:MLTX) with a bid exceeding $3 billion.

Merck & Co. Inc. closed 42.70% short of its 52-week high of $134.63, which the company reached on June 25th.

Merck & Co., Inc. (NYSE: MRK) has explored a potential acquisition of Swiss biotech firm MoonLake Immunotherapeutics in a ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

which could take on rival Merck & Co's best-selling drug Keytruda. The data may change how patients are treated following a diagnosis for advanced triple-negative breast cancer, one expert said.